Moderna (MRNA) Cash from Financing Activities (2018 - 2026)

Moderna (MRNA) has reported Cash from Financing Activities for 9 consecutive years, with $14.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 55.56% year-over-year to $14.0 million in Q2 2026; TTM through Jun 2026 was $611.0 million, a 2809.52% increase from a year earlier, with the FY2025 full-year figure at $593.0 million, up 958.93% from the prior year.
• Cash from Financing Activities was $14.0 million for Q2 2026 at Moderna, down from $17.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $581.0 million in Q4 2025 and troughed at -$1.3 billion in Q2 2022.
• A 5-year average of -$230.3 million and a median of -$2.0 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 51950.0% in 2022 and surged 19466.67% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$438.0 million in 2022, then surged by 75.11% to -$109.0 million in 2023, then soared by 97.25% to -$3.0 million in 2024, then surged by 19466.67% to $581.0 million in 2025, then plunged by 97.59% to $14.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $14.0 million (Q2 2026), $17.0 million (Q1 2026), and $581.0 million (Q4 2025), per Business Quant data.